To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

September 11, 2018

Today's Rundown

Featured Story

Former Gilead CMO Cheng joins Akero as CEO, as company moves HQ

After serving as Gilead’s CMO for just six months, Andrew Cheng has taken the top spot at Akero Therapeutics not long after the biotech raised $65 million to move its lead NASH candidate into phase 2 trials.

Top Stories

Crescendo names ex-Roche leader Pisa as CMO

Crescendo Biologics has named Pavel Pisa, M.D., Ph.D., as its chief medical officer. Pisa is the former group head of translational medicine at Roche, where he worked on the development of oncology drugs including Avastin and Gazyva. 

Appeals court hands Broad Institute a win in CRISPR patent feud

A federal appeals court handed the Broad Institute a win in a yearslong dispute Monday when it found there was “no interference-in-fact" between CRISPR patents held by Broad and patents sought by the University of California.

ImmusanT to develop Type 1 diabetes vaccine with JDRF backing

ImmusanT is expanding its vaccine immunotherapy platform to include Type 1 diabetes, following an investment from the JDRF.

Biodesy eyes expansion into therapeutics R&D with new CEO and $20M in VC funding

As it looks to expand into biologics discovery and development, molecule-monitoring company Biodesy announced it has brought in $20 million and appointed a new CEO to help drive industry adoption of its platform that detects real-time changes in protein structures.

OncoResponse raises $40M for cancer patient-sourced antibodies

Texas biotech OncoResponse has raised $40 million in second-round financing to develop drugs based on antibodies taken from cancer survivors.

Xenon frees itself of some XEN1101 milestone obligations

Xenon has struck a deal with Bausch Health to free itself from milestone and royalty obligations related to epilepsy prospect XEN1101. The agreement sees Xenon pay $6 million upfront to avoid having to hand over up to $40 million in milestones plus royalties down the line.

This gene mutation is key to glioblastoma’s ‘immortality’ and could point to drug targets

A mutation in a gene regulator called TERT is the most common mutation in glioblastoma, and it gives cancer cells the ability to divide and spread indefinitely. Researchers at the University of California, San Francisco, have discovered a new way to target the mutation and are working with GlaxoSmithKline to develop a drug based on the finding.

Resources

[Whitepaper] The Future of Pharmacovigilance: Leveraging Technology and Automation

Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be!

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

[Whitepaper] Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs

When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages.

[Whitepaper] Scale-Up and Technical Transfer for Lyophilized Products

Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale.

[Case Study] Identification of an Unknown Leachable Species from BFS Vials

In this case study, an unknown leachable species was detected by GC-MS analysis of an alkaline drug product (pH approximately 10.5) that was packaged in a novel self- contained plastic Blow Fill Seal (BFS) vial.

[Whitepaper] Addressing the Special Commercial Challenges in Rare Diseases

A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them.

[Webinar] Enabling precision medicine with Tableau and AWS

Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children.

[Paid Marketplace] Stability Testing & Storage

Catalent provides world class stability services to ease your critical path to success.

[Webinar] Build a holistic data management strategy for Life Sciences

Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS.

[Webinar] Safeguard your Life Sciences data with Druva and AWS

Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data.

[Whitepaper] Evolving Approaches to Drug Value Assessment in Global Markets

The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch.

Events

.